Description: We plan to incorporate living cell functionality with MEMS systems to develop a nanofabricated bioartificial kidney. The bioartificial kidney has the unique potential to improve the current treatment regimen for acute renal failure (ARF). ARF in intensive care unit patients continues to have mortality rates exceeding 70% despite hemodialysis or continuous venovenous hemofiltration (CVVH)
|
|
|
Innovative BioTherapies, Inc. |
$1,869 |
|
For-Profit |
Ann Arbor,
MI
|
|
Citation
|
Source:
Appropriations Report Language - Conference
|
Reference:
108-622
|
Location:
Line 29, Page 255
|
Citation Excerpt: Nanofabricated Bioartificial Kidney
|
|